Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CA4 | P22748 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | NOS1 | P29475 | 4/20 | 0.31 |
| ▸ | NOS3 | P29474 | 3/20 | 0.31 |
| ▸ | NOS2 | P35228 | 3/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17800108 | 1.00 | CA1 (0.39) | CA1CA2CA4ALDH1A1NOS1 | |
| SCHEMBL7269126 | 1.00 | CA1 (0.39) | CA1CA2CA4ALDH1A1NOS1 | |
| SCHEMBL7269122 | 1.00 | CA1 (0.39) | CA1CA2CA4ALDH1A1NOS1 | |
| SCHEMBL6592044 | 0.94 | — | — | |
| SCHEMBL6240345 | 0.91 | CA1 (0.48) | CA1CA2CA4ALDH1A1NOS1 | |
| SCHEMBL23952890 | 0.88 | CA1 (0.46) | CA1CA2CA4ALDH1A1NOS1 | |
| SCHEMBL6250904 | 0.88 | CA1 (0.46) | CA1CA2CA4ALDH1A1NOS1 | |
| SCHEMBL3318924 | 0.88 | CA1 (0.46) | CA1CA2CA4ALDH1A1NOS1 | |
| SCHEMBL6894837 | 0.88 | CA1 (0.46) | CA1CA2CA4ALDH1A1NOS1 | |
| SCHEMBL7724695 | 0.88 | CA1 (0.46) | CA1CA2CA4ALDH1A1NOS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240293551-A1 | USE OF ST-TYPE LIPID COMPOUNDS IN PREPARATION OF NUCLEIC ACID DELIVERY REAGENT AND RELATED PRODUCT | BEIJING BAISHIHEKANG PHARMACEUTICAL TECHNOLOGY (BSJPHARMA) CO., LTD (CN) | 2024-09-05 | — | — | US | disclosed |
| EP-3110810-B1 | PYRAZOLE AMIDE DERIVATIVE | TEIJIN PHARMA LTD (JP) | 2018-05-02 | — | — | EP | disclosed |
| EP-3110810-A1 | PYRAZOLE AMIDE DERIVATIVE | Teijin Pharma Limited (JP) | 2017-01-04 | — | — | EP | disclosed |
| US-9365522-B2 | Pyrazole amide derivative | AMGEN INC. (US) | 2016-06-14 | — | — | US | disclosed |
| US-20150266824-A1 | Pyrazole Amide Derivative | TEIJIN LIMITED (JP) | 2015-09-24 | — | — | US | disclosed |
| WO-2015129926-A1 | PYRAZOLE AMIDE DERIVATIVE | TEIJIN PHARMA LIMITED (JP) | 2015-09-03 | — | — | WO | disclosed |
| EP-2459603-B1 | POLYMERIZATION PROCESS USING A SUPPORTED CONSTRAINED GEOMETRY CATALYST | UNIVATION TECH LLC (US) | 2014-07-02 | — | — | EP | disclosed |
| WO-2010094810-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR TREATING TUBERCULOSIS | N.V. ORGANON (NL) | 2010-08-26 | — | — | WO | disclosed |
| WO-2009023201-A1 | RIGID DERIVATIVES OF TRIPTOLIDE AS ANTICANCER, IMMUNE SUPPRESSANT, ANTI-FIBROSIS, AND CNS PROTECTANT AGENTS | MYELORX LLC (US) | 2009-02-19 | — | — | WO | disclosed |
| EP-0823423-B1 | 1,4-DISUBSTITUTED PIPERIDINE DERIVATIVES | BANYU PHARMA CO LTD (JP) | 2004-06-16 | — | — | EP | disclosed |
| US-6538145-B2 | Having a hydroxy group at 24-position and, optionally, a substituent at 2 beta position; reacting intermediates of the A ring part and intermediates of the C ring; cyclization; coupling; control of calcium metabolism; antitumor agents | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2003-03-25 | — | — | US | disclosed |
| US-6140338-A | FOR TREATING ACUTE INFLAMMATORY DISEASES, CHRONIC INFLAMMATORY DISEASES, ACQUIRED IMMUNE DEFICIENCY SYNDROME, CANCER, ISCHEMIC REFLOW DISORDER AND/OR ARTERIOSCLEROSIS | BANYU PHARMACEUTICAL, CO., LTD. (JP) | 2000-10-31 | — | — | US | disclosed |
| EP-0916668-A1 | CHEMOKINE RECEPTOR ANTAGONISTS | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1999-05-19 | — | — | EP | disclosed |
| EP-0823423-A1 | 1,4-DISUBSTITUTED PIPERIDINE DERIVATIVES | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1998-02-11 | — | — | EP | disclosed |
| EP-0089815-B1 | LIQUID PERFLUOROCARBONS, FOR USE IN OCULAR THERAPY, AND PREPARATIONS CONTAINING THEM | Haidt, Sterling Joel (US) | 1986-12-17 | — | — | EP | disclosed |
| EP-0089232-B1 | PERFLUOROCARBON LIQUIDS USEFUL IN EYE TREATMENT AND DIAGNOSTIC PROCEDURES | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 1986-07-02 | — | — | EP | disclosed |
| US-4289499-A | BY DETERMINATION OF CRITICAL SOLUTION TEMPERATURE | CHILDRENS HOSPITAL MEDICAL CENTER (US) | 1981-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150266824-A1 | Pyrazole Amide Derivative | RORC, RORB, RORA | CA1 3025/4885CA2 2948/4885CA4 2578/4885 |
| US-20240293551-A1 | USE OF ST-TYPE LIPID COMPOUNDS IN PREPARATION OF NUCLEIC ACID DELIVERY REAGENT AND RELATED PRODUCT | POLRMT, LIPC, POLM | CA1 4546/4885CA2 3345/4885CA4 2625/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.